Aptus Pharma
add_icon

Aptus Pharma

322.85
-322.85
(-100.00%)
Market Cap
221.50 Cr
PE Ratio
-
Volume
0.00
Day High - Low
- - -
52W High-Low
364.00 - 80.80
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
221.50 Cr
EPS
6.37
PE Ratio
-
PB Ratio
11.08
Book Value
29.13
EBITDA
4.90
Dividend Yield
0.00 %
Return on Equity
44.50
Debt to Equity
1.79
Forecast For
Actual

Company News

View All News
Caret
positive
Aptus Pharma Limited has scheduled a board meeting for March 24, 2026, to consider increasing authorized share capital and recommending bonus equity shares to shareholders.
positive
Aptus Pharma Limited announces strategic business expansion into Life-Saving Injectables and ICU Care product category, targeting critical care conditions and hospital settings.
positive
Aptus Pharma Limited receives recognition as 'Fastest Growing Ethical Pharma Company' from News 18 Group, with award presented by Gujarat's Deputy Chief Minister Harsh Sanghavi.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,526.60
#1 1,03,621.39
61.40
#1 24,630.60
14.26
#1 2,203
-61.57
46.74
1,347.20
44,576.79
95.64
15,737.30
23.58
834
-35.40
34.96
1,733.50
35,643.32
75.68
12,042.70
23.73
591
-39.17
34.95
6,677.00
23,484.37
131.72
10,046.60
#1 48.08
251
-125.14
40.12
242.45
15,611.72
34.22
7,932.40
7.48
564
-9.74
40.24
324.05
14,139.75
50.48
5,598.70
14.48
314
-5.15
52.63
811.70
10,298.19
#1 31.94
8,110.20
15.97
363
-39.55
36.93
456.75
8,833.71
54.58
2,451.50
11.53
164
-71.43
42.49
484.45
6,634.59
83.76
2,789.50
1.31
108
-44.50
41.59
782.80
5,375.60
35.06
1,622.70
34.46
213
#1 300.00
41.40
Growth Rate
Revenue Growth
37.43 %
Net Income Growth
287.50 %
Cash Flow Change
15.21 %
ROE
-1.51 %
ROCE
105.69 %
EBITDA Margin (Avg.)
127.53 %

Yearly Financial Results

Annual Financials
2023
2024
2025
TTM
Revenue
14
18
25
0
Expenses
13
16
20
0
EBITDA
1
2
5
0
Operating Profit %
4 %
9 %
20 %
0 %
Depreciation
0
0
0
0
Interest
0
0
1
0
Profit Before Tax
0
1
4
0
Tax
0
0
1
0
Net Profit
0
1
3
0
EPS in ₹
1.30
5.32
6.37
0.00

Balance Sheet

Balance Sheet
2023
2024
2025
Total Assets
6
10
22
Fixed Assets
1
1
1
Current Assets
6
8
20
Capital Work in Progress
0
0
0
Investments
0
0
0
Other Assets
6
9
21
Total Equity & Liabilities
6
10
22
Current Liabilities
3
4
12
Non Current Liabilities
2
4
3
Total Equity
1
2
7
Reserve & Surplus
1
2
2
Share Capital
0
0
5

Cash Flow

Cash Flow
2023
2024
2025
Net Cash Flow
0
0
4
Investing Activities
-0
-0
-1
Operating Activities
-0
-2
-2
Financing Activities
1
3
7

Share Holding

% Holding
Jun 2025
Sept 2025
Dec 2025
Promoter
72.89 %
72.89 %
72.89 %
FIIs
10.03 %
10.03 %
0.00 %
DIIs
2.80 %
2.80 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
Public / Retail
11.55 %
11.55 %
22.97 %
Others
2.74 %
2.74 %
4.14 %
No of Share Holders
9
9
302

Announcements

Closure of Trading Window2 days ago
Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Tuesday March 24 20262 days ago
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015: Business ExpansionFeb 26, 2026
Intimation Of Award Received: Recognition As Fastest Growing Ethical Pharma CompanyFeb 24, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 07, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2026
Press Release- Aptus Pharma Expands OTC Presence In Gujarat Strengthens Cosmeceutical PortfolioDec 12, 2025
Regulation 30 Disclosure - Entry Into The Urology Therapy SegmentNov 21, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 12, 2025
Intimation Of New Product- ENZYKING SYRUPNov 12, 2025
Intimation Of New Product- SHIROVITA HAIR OIL (AYURVEDIC HAIR OIL)Nov 12, 2025
Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 11, 2025
Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 10, 2025
Board Meeting Outcome for Board Meeting Outcome For Approval Of Unaudited Financial Results For The Half Year Ended On 30Th September 2025Nov 10, 2025
Board Meeting Intimation for To Consider And Take On Record Of The Un-Audited Financial Results For The Half Year Ended On 30Th September 2025.Nov 01, 2025
Clarification On Price MovementOct 21, 2025
Clarification sought from Aptus Pharma LtdOct 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Closure of Trading WindowOct 01, 2025
Listing of Equity Shares of Aptus Pharma LtdSep 30, 2025

Technical Indicators

RSI(14)
Neutral
70.16
ATR(14)
Less Volatile
11.37
STOCH(9,6)
Overbought
87.36
STOCH RSI(14)
Neutral
60.53
MACD(12,26)
Bullish
5.20
ADX(14)
Strong Trend
41.86
UO(9)
Bearish
67.21
ROC(12)
Uptrend And Accelerating
21.08
WillR(14)
Neutral
-40.05